Antioksidativno djelovanje metanolnih ekstrakata listova sedam egipatskih vrsta roda Cassia

In the present study, antioxidant activity of methanolic extracts of the leaves of seven Egyptian Cassia species was investigated using two methods, the phosphomolybdate method and 1,1 diphenyl-2-picrylhydrazyl radical (DPPH•) scavenging activity method. The results revealed that C. glauca is the most potent species and that the activity of other plant species decreases in the following order C. grandis > C. nodosa > C. fistula > C. didymobtrya > C. occidentalis > C. sophera. Defatted methanolic extract of the most active plant C. glauca was subjected to fractionation process using different organic solvents such as CHCl3, EtOAc and BuOH. Antioxidant activities of these fractions were investigated and the results showed that ethyl acetate fraction possessed high activity. Total phenolic and flavonoid concentration of each plant extract were determined using the Folin-Ciocaltu reagent and aluminum chloride. Correlation between radical scavenging capacities of extracts and total phenolic concentration was observed.U radu je ispitano antioksidativno djelovanje metanolnih ekstrakata listova sedam egipatskih vrsta roda Cassia koristeći fosfomolibdatnu metodu i metodu vezanja slobodnih 1,1-difenil-2-pikrilhidrazil radikala (DPPH.). Rezultati pokazuju da C. glauca ima najveću aktivnost te da se djelovanje smanjuje sljedećim redom: C. grandis C. nodosa C. fistula C. didymobtrya C. occidentalis C. sophera. Odmašćeni metanolni ekstrakt najaktivnije biljke C. glauca frakcioniran je pomoću različitih organskih otapala kao što su CHCl3, EtOAc i BuOH. Ispitivanje antioksidativnog djelovanja pojedinih frakcija pokazuje da je etil-acetatna frakcija najaktivnija. Pomoću Folin-Ciocaltuovog reagensa i aluminijevog klorida određena je ukupna koncentracija fenola i flavonoida svakog pojedinog ekstrakta. Uočena je korelacija između sposobnosti hvatanja slobodnih radikala i ukupnog sadržaja fenola

Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study

OBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally